Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solithromycin - Melinta Therapeutics

Drug Profile

Solithromycin - Melinta Therapeutics

Alternative Names: CEM-101; OP-1068; T-4288

Latest Information Update: 29 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; FUJIFILM Toyama Chemical; Melinta Therapeutics; Toyama Chemical
  • Class Anti-infectives; Antibacterials; Antimalarials; Heterocyclic bicyclo compounds; Ketolides; Macrolides; Oxazoles; Pyrans; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia
  • Phase III Bronchitis; Chlamydial infections; Gonorrhoea; Otorhinolaryngological infections; Respiratory tract infections; Sinusitis; Urethritis
  • Phase II Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis
  • Preclinical Eye disorders
  • No development reported Anthrax; Bacterial infections; Cystic fibrosis; Enterococcal infections; Legionella infections; Malaria; Mycobacterium avium complex infections; Mycoplasma infections; Obstetric and gynaecological infections; Otitis media; Tularaemia

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In volunteers) in Japan (PO, Tablet)
  • 02 Oct 2018 Toyama Chemical completes a phase III trial in Community-acquired pneumonia in Japan (PO) (JapicCTI163439)
  • 02 Oct 2018 Toyama Chemical completes a phase III trial in Respiratory tract infections and Bronchitis in Japan (PO) (JapicCTI163438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top